Taro Pharmaceuticals, Once Nearly Broke, Now Has $6 Billion Market Cap

Taro’s ability to raise prices seems surprising considering the reputation of the generic drug market. In its financial reports, the company mentions competition, but industry sources and data paint a different picture.

Yoram Gabison
Reuters
Send in e-mailSend in e-mail
Dilip Shanghvi, chairman and managing director of Sun Pharmaceutical Industries Ltd.Credit: Bloomberg News

Comments